## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.7% below STRENGTH zone (3.0-6.0%); PEG 1.30 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($313.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. UnitedHealth exits South America with Banmedica sale**
- Source: MSN | 20251217T190442 | Bearish | Relevance: 100%
- UnitedHealth has announced its complete exit from the South American market by selling its Chilean health business, Banmedica. The sale marks a strategic shift for the U.S. healthcare giant, divesting its remaining operations in the region.

**2. UnitedHealth Group (UNH) Stock Today: Latest News, Analyst Forecasts, and What Investors Are Watching on Dec. 16, 2025**
- Source: ts2.tech | 20251216T160906 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) is under investor scrutiny on December 16, 2025, due to a dividend payment, upcoming full-year 2025 results and 2026 guidance, and significant regulatory and legal headlines affecting its Optum business. While the stock is experiencing a slight dip, investors are closely watching for clarity on medical cost trends and Medicare Advantage profitability. Analyst consensus remains broadly "Buy" with an average 12-month target of $392.24, despite ongoing volatility and regulatory pressures.

**3. UnitedHealth Group (UNH) Stock After Hours Today (Dec. 15, 2025): Key News, Analyst Forecasts, and What to Watch Before Tuesdayâ€™s Open**
- Source: ts2.tech | 20251216T000848 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) stock saw a modest dip in after-hours trading, influenced by broader industry concerns like rising medical costs and regulatory pressures, highlighted by a rival's downgrade. Investors are advised to watch key macroeconomic data releases on Tuesday morning, including jobs and retail sales reports, as these are expected to heavily impact market sentiment. UNH's next major catalyst will be its full-year 2025 results and 2026 guidance, scheduled for January 27, 2026.

**4. UnitedHealth Exits South America With Banmedica Sale**
- Source: Yahoo! Finance Canada | 20251217T185542 | Neutral | Relevance: 100%
- UnitedHealth Group has agreed to sell Banmedica, its final South American operation, to Brazilian private equity firm Patria Investments for $1 billion. This sale completes UnitedHealth's withdrawal from Latin America, a process that began in 2022 and has incurred an $8.3 billion loss for the company. The exit allows CEO Stephen Hemsley to refocus on core business growth, with projections for momentum to build into 2027.

**5. UnitedHealth Group Incorporated $UNH Shares Sold by Venture Visionary Partners LLC**
- Source: MarketBeat | 20251217T141510 | Neutral | Relevance: 100%
- Venture Visionary Partners LLC significantly reduced its stake in UnitedHealth Group Incorporated (NYSE:UNH) by 42.0% in the third quarter, selling 7,686 shares and retaining 10,610 shares valued at $3,664,000. Other institutional investors like Geode Capital Management LLC and Norges Bank increased their holdings, while analysts provided mixed ratings with a consensus "Hold" and an average price target of $385.54. The company recently reported strong quarterly earnings, beating estimates, and announced a quarterly dividend of $2.21 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 7.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.30 suggests fair value with growth premium. Forward P/E 18.7x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $300.4B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.30 |
| Forward P/E | 18.7 |
| Current P/E | 20.3 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 2.7% (minimal 5-day change). Below STRENGTH zone by 0.3pp (needs >3.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Below SMA200 (0.93x), long-term trend not supportive. MACD histogram positive (1.55), confirming momentum. RSI neutral at 50. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.68% (CS: 52) | Neutral |
| RSI_14 | 49.7 | Neutral |
| MACD Histogram | 1.55 | Bullish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 0.930x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $331.47
- **Stop Loss:** $313.87 (5.3% risk)
- **Target:** $349.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 61
- **Position Value:** $20,219.67
- **Portfolio %:** 20.22%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*